Cargando...
LRRK2 G2019S Mutations are associated with an increased cancer risk in Parkinson Disease
Leucine rich repeat kinase (LRRK2) G2019S mutations are presumed to cause PD through a toxic gain of function of the protein kinase. Small molecule kinase inhibitors have been developed for the treatment of certain cancers, and some antioncogenic agents such as sunitinib, may non-specifically inhibi...
Gardado en:
| Main Authors: | , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2010
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2978749/ https://ncbi.nlm.nih.gov/pubmed/20818610 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/mds.23314 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|